Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Akero Therapeutics Inc. (AKRO) Insider Trading Activity
Healthcare • Biotechnology • 61 employees
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Total Value
-$8,642,781.28
Total Shares
353,984
Average Trade Value
-$90,028.97
Most Active Insider
Cheng Andrew
Total Activity: $15,367,678
Largest Single Transaction
$9,600,000
by Graham G. Walmsley on Jan 30, 2025
30-Day Activity
2 Transactions
Volume: 50,000 shares
Value: $2,243,213
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Operating Officer
|
Mar 4, 2025 | 11,447 | $505,591 | 239,700 (-4.8%) | Sale | |
|
Chief Operating Officer
|
Mar 4, 2025 | 38,553 | $1,737,622 | 201,147 (-19.2%) | Sale | |
|
Senior Vp, Commercial Strategy
|
Mar 3, 2025 | 1,000 | $48,090 | 33,492 (-3.0%) | Sale | |
|
Senior Vp, Commercial Strategy
|
Mar 3, 2025 | 1,000 | $19,870 | 34,492 (+2.9%) | Exercise/Conversion | |
|
Chief Development Officer
|
Feb 18, 2025 | 10,000 | $211,000 | 105,648 (+9.5%) | Exercise/Conversion | |
|
Chief Development Officer
|
Feb 18, 2025 | 9,100 | $453,089 | 96,548 (-9.4%) | Sale | |
|
Chief Development Officer
|
Feb 18, 2025 | 900 | $45,571 | 95,648 (-0.9%) | Sale | |
|
President and CEO
|
Feb 10, 2025 | 12,640 | $654,145 | 703,422 (-1.8%) | Sale | |
|
President and CEO
|
Feb 10, 2025 | 9,972 | $535,157 | 687,011 (-1.5%) | Sale | |
|
President and CEO
|
Feb 10, 2025 | 200 | $11,162 | 686,062 (-0.0%) | Sale | |
|
President and CEO
|
Feb 10, 2025 | 6,439 | $340,675 | 696,983 (-0.9%) | Sale | |
|
President and CEO
|
Feb 10, 2025 | 749 | $40,855 | 686,262 (-0.1%) | Sale | |
|
Chief Scientific Officer
|
Feb 5, 2025 | 18,750 | $395,625 | 188,987 (+9.9%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Feb 5, 2025 | 5,903 | $336,022 | 170,237 (-3.5%) | Sale | |
|
Chief Scientific Officer
|
Feb 5, 2025 | 12,847 | $723,607 | 176,140 (-7.3%) | Sale | |
|
Chief Operating Officer
|
Feb 3, 2025 | 5,100 | $273,182 | 256,047 (-2.0%) | Sale | |
|
Chief Operating Officer
|
Feb 3, 2025 | 4,900 | $264,879 | 251,147 (-2.0%) | Sale | |
| Jan 30, 2025 | 200,000 | $9,600,000 | 1,000,000 (+20.0%) | Purchase | ||
|
Chief Scientific Officer
|
Jan 27, 2025 | 14,986 | $297,772 | 185,223 (+8.1%) | Exercise/Conversion | |
|
Senior Vp, Commercial Strategy
|
Jan 27, 2025 | 4,000 | $79,480 | 38,492 (+10.4%) | Exercise/Conversion | |
|
Senior Vp, Commercial Strategy
|
Jan 27, 2025 | 5,000 | $285,150 | 33,492 (-14.9%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 15,172 | $96,555 | 127,669 (+11.9%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 27, 2025 | 5,059 | $281,382 | 182,616 (-2.8%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 16,849 | $10,362 | 112,497 (+15.0%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 27, 2025 | 16,264 | $343,170 | 201,487 (+8.1%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 27, 2025 | 12,379 | $705,232 | 170,237 (-7.3%) | Sale | |
|
Chief Scientific Officer
|
Jan 27, 2025 | 13,812 | $756,345 | 187,675 (-7.4%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 27,340 | $1,559,036 | 95,648 (-28.6%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 9,250 | $517,528 | 122,988 (-7.5%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 8,700 | $495,961 | 95,648 (-9.1%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 14,467 | $809,429 | 104,348 (-13.9%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 49,074 | $1,035,461 | 144,722 (+33.9%) | Exercise/Conversion | |
|
Chief Development Officer
|
Jan 27, 2025 | 17,000 | $937,652 | 132,238 (-12.9%) | Sale | |
|
Chief Development Officer
|
Jan 27, 2025 | 21,569 | $454,890 | 149,238 (+14.5%) | Exercise/Conversion | |
|
Chief Development Officer
|
Jan 27, 2025 | 25,907 | $1,428,823 | 118,815 (-21.8%) | Sale | |
|
President and CEO
|
Jan 27, 2025 | 2,381 | $132,217 | 719,439 (-0.3%) | Sale | |
|
President and CEO
|
Jan 27, 2025 | 3,377 | $192,118 | 716,062 (-0.5%) | Sale | |
|
President and CEO
|
Jan 27, 2025 | 24,242 | $1,322,644 | 721,820 (-3.4%) | Sale | |
|
Chief Operating Officer
|
Jan 24, 2025 | 43,064 | $274,059 | 261,147 (+16.5%) | Exercise/Conversion | |
|
President and CEO
|
Jan 23, 2025 | 50,000 | $30,750 | 746,062 (+6.7%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Jan 2, 2025 | 10,000 | $280,330 | 218,083 (-4.6%) | Sale | |
|
Senior Vp, Commercial Strategy
|
Dec 31, 2024 | 234 | $4,607 | 34,492 (+0.7%) | Grant | |
|
Chief Scientific Officer
|
Dec 17, 2024 | 3,800 | $75,506 | 182,137 (+2.1%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Dec 17, 2024 | 3,800 | $118,172 | 178,337 (-2.1%) | Sale | |
|
Chief Development Officer
|
Dec 16, 2024 | 9,074 | $191,461 | 104,722 (+8.7%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 16, 2024 | 24,300 | $0 | 62,635 (+38.8%) | Grant | |
|
Chief Technology Officer
|
Dec 16, 2024 | 24,300 | $0 | 24,300 (+100.0%) | Grant | |
|
Senior Vp, Commercial Strategy
|
Dec 16, 2024 | 17,400 | $0 | 35,258 (+49.4%) | Grant | |
|
Chief Development Officer
|
Dec 16, 2024 | 9,074 | $264,117 | 95,648 (-9.5%) | Sale | |
|
Senior Vp, Commercial Strategy
|
Dec 16, 2024 | 1,000 | $29,130 | 34,258 (-2.9%) | Sale | |
|
President and CEO
|
Dec 16, 2024 | 98,500 | $0 | 696,062 (+14.2%) | Grant | |
|
Chief Development Officer
|
Dec 16, 2024 | 24,300 | $0 | 95,648 (+25.4%) | Grant | |
|
Chief Scientific Officer
|
Dec 16, 2024 | 20,000 | $0 | 198,337 (+10.1%) | Grant | |
|
Chief Operating Officer
|
Dec 16, 2024 | 24,300 | $0 | 228,083 (+10.7%) | Grant | |
|
President and CEO
|
Dec 10, 2024 | 7,855 | $241,855 | 597,562 (-1.3%) | Sale | |
|
Senior Vp, Commercial Strategy
|
Dec 10, 2024 | 925 | $28,481 | 17,858 (-5.2%) | Sale | |
|
Chief Financial Officer
|
Dec 10, 2024 | 2,817 | $86,735 | 38,335 (-7.3%) | Sale | |
|
Chief Development Officer
|
Dec 10, 2024 | 2,810 | $86,520 | 71,348 (-3.9%) | Sale | |
|
Chief Scientific Officer
|
Dec 10, 2024 | 2,450 | $48,682 | 180,787 (+1.4%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Dec 10, 2024 | 2,503 | $77,067 | 203,783 (-1.2%) | Sale | |
|
Chief Scientific Officer
|
Dec 10, 2024 | 2,450 | $76,024 | 178,337 (-1.4%) | Sale | |
|
Chief Scientific Officer
|
Dec 10, 2024 | 2,368 | $72,911 | 178,337 (-1.3%) | Sale | |
|
President and CEO
|
Dec 2, 2024 | 25,000 | $802,250 | 605,417 (-4.1%) | Sale | |
|
Chief Operating Officer
|
Dec 2, 2024 | 10,000 | $321,310 | 206,286 (-4.8%) | Sale | |
|
President and CEO
|
Dec 2, 2024 | 25,000 | $527,500 | 630,417 (+4.0%) | Exercise/Conversion | |
|
Chief Development Officer
|
Nov 15, 2024 | 300 | $8,647 | 74,158 (-0.4%) | Sale | |
|
Chief Development Officer
|
Nov 15, 2024 | 9,061 | $191,187 | 83,219 (+10.9%) | Exercise/Conversion | |
|
Chief Development Officer
|
Nov 15, 2024 | 8,761 | $242,627 | 74,458 (-11.8%) | Sale | |
|
Chief Development Officer
|
Nov 6, 2024 | 10,000 | $351,890 | 74,158 (-13.5%) | Sale | |
|
Chief Development Officer
|
Nov 6, 2024 | 10,000 | $6,150 | 84,158 (+11.9%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Nov 1, 2024 | 15,481 | $499,525 | 216,578 (-7.1%) | Sale | |
|
President and CEO
|
Nov 1, 2024 | 81,280 | $1,715,008 | 686,697 (+11.8%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Nov 1, 2024 | 292 | $9,618 | 216,286 (-0.1%) | Sale | |
|
Chief Development Officer
|
Nov 1, 2024 | 15,485 | $505,105 | 74,158 (-20.9%) | Sale | |
|
Chief Development Officer
|
Nov 1, 2024 | 15,485 | $326,734 | 89,643 (+17.3%) | Exercise/Conversion | |
|
President and CEO
|
Nov 1, 2024 | 27,086 | $880,268 | 605,417 (-4.5%) | Sale | |
|
Chief Operating Officer
|
Nov 1, 2024 | 34,943 | $1,092,109 | 232,059 (-15.1%) | Sale | |
|
President and CEO
|
Nov 1, 2024 | 27,086 | $571,515 | 632,503 (+4.3%) | Exercise/Conversion | |
|
President and CEO
|
Nov 1, 2024 | 81,280 | $2,558,044 | 605,417 (-13.4%) | Sale | |
|
Chief Operating Officer
|
Nov 1, 2024 | 40,716 | $858,700 | 267,002 (+15.2%) | Exercise/Conversion | |
|
Chief Development Officer
|
Oct 30, 2024 | 4,515 | $146,855 | 74,158 (-6.1%) | Sale | |
|
Chief Development Officer
|
Oct 30, 2024 | 4,515 | $95,267 | 78,673 (+5.7%) | Exercise/Conversion | |
|
President and CEO
|
Oct 18, 2024 | 226 | $7,259 | 605,417 (-0.0%) | Sale | |
|
President and CEO
|
Oct 18, 2024 | 63,313 | $1,996,069 | 605,643 (-10.5%) | Sale | |
|
President and CEO
|
Oct 18, 2024 | 63,539 | $1,340,673 | 668,956 (+9.5%) | Exercise/Conversion | |
|
President and CEO
|
Oct 17, 2024 | 3,103 | $65,473 | 608,520 (+0.5%) | Exercise/Conversion | |
|
President and CEO
|
Oct 17, 2024 | 3,103 | $96,559 | 605,417 (-0.5%) | Sale | |
|
President and CEO
|
Oct 16, 2024 | 24,992 | $778,151 | 605,417 (-4.1%) | Sale | |
|
President and CEO
|
Oct 16, 2024 | 24,992 | $527,331 | 630,409 (+4.0%) | Exercise/Conversion | |
|
Chief Development Officer
|
Oct 15, 2024 | 14,825 | $9,117 | 90,119 (+16.5%) | Exercise/Conversion | |
|
Chief Development Officer
|
Oct 15, 2024 | 14,525 | $442,954 | 75,594 (-19.2%) | Sale | |
|
Chief Development Officer
|
Oct 15, 2024 | 300 | $9,278 | 75,294 (-0.4%) | Sale | |
|
Chief Development Officer
|
Oct 14, 2024 | 5,000 | $3,075 | 80,294 (+6.2%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Oct 14, 2024 | 40,000 | $1,206,080 | 226,286 (-17.7%) | Sale | |
|
Chief Operating Officer
|
Oct 14, 2024 | 40,000 | $843,600 | 266,286 (+15.0%) | Exercise/Conversion | |
|
Chief Development Officer
|
Oct 14, 2024 | 6,136 | $184,258 | 74,158 (-8.3%) | Sale |